Evidence map›Paper›PMID 42853026›Full record

ArticleImmunity, inflammation and disease2026

A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast-Acting Treatment for Impeding Crisis of MuSK-MG.

Tianjiao Duan, Song Ouyang, Wei Lu, Weifan Yin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tianjiao DuanDepartment of Neurology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID https://orcid.org/0009-0007-6816-4844
Song OuyangDepartment of Neurology, the Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Wei LuDepartment of Neurology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Weifan YinDepartment of Neurology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

National Natural Science Foundation of China 82101422Natural Science Foundation of Hunan Province 2022JJ40680Natural Science Foundation of Hunan Province 2023JJ30062Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University
6 · The paper itself

Abstract

backgroundMyasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The muscle-specific kinase (MuSK) antibody-positive subtype often involves bulbar and respiratory muscles, conferring a high risk of myasthenic crisis.

methodWe report a very late-onset MuSK-MG case complicated by lung infection and acute heart failure, with a history of peptic ulcer. The patient was sequentially treated with efgartigimod and telitacicept, achieving minimal symptom expression (MSE) within 1.5 months. DISCUSSION: Following the first efgartigimod infusion, QMG and MG-ADL scores improved from 31 to 23 and 22 to 12, respectively. After five injections of telitacicept, symptoms resolved completely on day 47, with scores further reducing to 2 (QMG) and 0 (MG-ADL). Treatment also reduced IgG levels and MuSK-Ab titers, while IgM remained stable.

conclusionThis case demonstrates the successful sequential use of efgartigimod and telitacicept in managing complicated, late-onset MuSK-MG in a state of impeding crisis.

Indexed as

Myasthenia GravisReceptor Protein-Tyrosine KinasesReceptors, CholinergicRecombinant Fusion ProteinsAutoantibodiesHumansTreatment OutcomeAutoantibodiesMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, CholinergicRecombinant Fusion Proteinstelitaciceptefgartigimodimpeding crisismuscle‐specific kinasemyasthenia gravistelitacicept

Identifiers

PMID42853026
PMCPMC13651717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.